VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor, VIC-1911, and G12C Inhibitor, Sotorasib, for KRAS G12C-Mutant Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

By / 05/06/2023

VITRAC Therapeutics, LLC presented a poster on the Phase 1a/1b clinical trial of aurora kinase A inhibitor, VIC-1911, as monotherapy and in combination with KRAS G12C inhibitor, sotorasib.